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SUMMARY. The fi rst organized national cytology screening program for detecting cervical lesions in Croatia was initi-
ated at the end of 2012. This screening program is currently under review. The working proposal is to screen women 
aged 20–29 by cytology alone, those aged 30–34 by cytology and hrHPV cotesting, and woman 35–64 years old by high 
risk Human papillomavirus (hrHPV testing) without cytology cotesting. The objective is to contribute to the selection of 
cervical screening options among various possibilities in our population. Methods: We conducted a retrospective analy-
sis of preceding cervicovaginal cytology and hrHPV test results in biopsy proven HSIL between January 1, 2016 and 
December 31, 2016. This included 143 HSIL cases from patients aged 18–85. Results: In detecting HSIL Pap test has 
been abnormal in 99% (142/143), and hrHPV test in 80% (115/143). The cytology, analyzed within one year prior to the 
HSIL biopsy, has reported ASC-H/HSIL in 87% (125/143) cases, whereas 12% (17/143) and 0.7% (1/143) have reported 
ASC-US/LSIL and negative respectively. The hrHPV negative test has been found in 13% (5/39) of the 20–29 age group, 
21% (7/33) of the 30–34 age group, and 22% (15/68) of the 35–65 age group. Conclusions: Our data suggest that 
 approximately 22% of analyzed woman in the 35–64 age group may be misdiagnosed for HSIL, when using HPV testing 
as the only cervical screening method. The widespread replacement of cytology by hrHPV testing should be subject to 
further investigation and given careful consideration.
Introduction
Cytology based screening for cervical cancer has sig-
nifi cantly decreased both cervical cancer rates and mor-
tality since its widespread implementation in high in-
come countries in the early 1970s.1–3 Cervical cancer 
screening detects preinvasive cervical lesions, allowing 
less harmful treatment possible before the disease be-
comes invasive, as well as detecting the invasive dis-
ease. Persistent human papillomavirus (HPV) infection 
is a crucial part of the causative pathway in cervical 
cancer pathogenesis and may be detected prior to devel-
opment of preinvasive disease.4
Screening is performed using cervical cytology (Pap 
test) or a hrHPV (high risk Human papillomavirus) test, 
or by applying both of them.5–7 The annual Pap test to 
screen for cervical cancer was the most successful can-
cer screening test ever developed.8 The Pap test can be 
analyzed as a conventional Pap (CP) triple smear (vagi-
nal/cervical/endocervical) or as a liquid based cytology 
(LBC) sample. In terms of cytology and hrHPV cotest-
ing, the greatest LBC advantage is that the same sample 
can be used for both methods.9 In Croatia, the vast ma-
jority of the Pap smears are CP due to lower cost. The 
LBC has been developed as an alternative to CP to im-
prove specimen adequacy and increase the sensitivity 
for detecting relevant cervical abnormalities.9,10 The re-
sults of the latter approach are, however disparate.11,12
In many countries with long term experience of orga-
nized cytology based screening an effort to prolong the 
screening interval and thus lower the burden on the 
health care system has been introduced.13–15 Since hrH-
PV infection precede cervical epithelial abnormalities, 
the hrHPV detection can prolong the screening interval. 
The effi cacy of prolonged human papilloma virus 
(HPV)-based screening has been documented in numer-
ous studies.5,16–22 However, some of the mentioned,5,21,22 
as well as additional studies23,24 present data of hrHPV 
tested negative HSIL (high-grade squamous intraepi-
thelial lesion) and invasive carcinoma cases. Despite 
these fi ndings, in some national screening programs of 
high income countries primary hrHPV testing has been 
introduced for cervical cancer screening (Australia, 
New Zealand, Netherlands).7 In most other high income 
countries, the national screening programs are still 
based on primary cytology or cytology (mostly LBC) 
and hrHPV cotesting with tendency to change to pri-
mary hrHPV testing in the close future.6,7,25 In the Unit-
ed States of America (USA), the current American So-
ciety of Clinical Oncology (ASCO) 2016 recommenda-
tions are primary hrHPV screening for women aged 
25–65 every 5 years,26 whereas the newest 2018 Ameri-
can Cancer Society (ACS), the American Society for 
Colposcopy and Cervical Pathology (ASCCP), the 
American Society for Clinical Pathology (ASCP), the 
US Preventive Services Task Force (USPSTF), and the 
American College of Obstetricians and Gynecologists 
(ACOG) guidelines recommend primary cytology ev-
ery 3 years for women aged 21–29, and for women aged 
30–65 cytology and hrHPV cotesting every 5 years or 
cytology alone every 3 years.27 The Japanese cervical 
cancer study concluded that the best strategy is cytolo-
gy and hrHPV cotesting with HPV 16/18 detection.28
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The fi rst probationary program for cervical cancer 
screening in Croatia was performed more than half a 
century ago in one district of Zagreb.29 Since that time, 
due to opportunistic screening, cervical cancer morbid-
ity and mortality in Croatia have been signifi cantly de-
creased. Although a signifi cant number of women regu-
larly perform a gynecologic exam and a Pap smear once 
per year, as has been recommended, there is still an un-
known but not negligible proportion of the population 
that remains unscreened.30 The fi rst organized national 
cytology based screening program for detecting cervi-
cal cancer in Croatia started at the end of 2012.31 Due to 
many problems, this program is under review, being 
placed on hold.32
The newest Croatian working proposal for cervical 
cancer screening involves women aged 20–29 by cytol-
ogy alone, those aged 30–34 by cytology and hrHPV 
cotesting, and only by hrHPV testing for those aged 
35–65.33
Material and Methods
Histopathologic diagnoses refer to the interpretation 
of surgical pathology specimens, including cervical bi-
opsies, endocervical curettage specimens, and/or diag-
nostic, excisional procedures using loop electrosurgical 
excision procedures or cold knife cervical conisation. 
HSIL diagnoses included cervical intraepithelial neo-
plasia (CIN) grade 2 and 3 (CIN2, CIN3) as well as and 
descriptive CIN due to damaged tissue, but suggesting 
HSIL.
In our study, 143 cases of histology proven HSIL 
with available both preoperative Pap and hrHPV tests 
results have been included. In particular, we have exam-
ined the available preoperative Pap test results and the 
hrHPV testing results in the Hospital database for all 
cases.
The last Pap test has been a conventional cervical 
smear analyzed mostly in our laboratory and the results 
have been reported in a form known as “Zagreb 2002”.34 
For cytologic-histologic correlation we considered Pap 
smears taken within 4 months and up to one year prior 
to a biopsy were supplemented with concomitantly col-
lected ones, unless there was no Pap test preceding to 
biopsy in that interval.35
The analysis is complemented by the Pap smears re-
corded in our Hospital database for the period from one 
to fi ve years prior to biopsy. In this context in terms of 
two-tiered terminology (LSIL/HSIL),4,36 negative cytol-
ogy is considered major undercall, ASC-US and LSIL 
(ASC-US/CIN1) minor undercall, whereas ASC-H and 
HSIL (ASC-H/HSIL) as agreement.37
The hrHPV tests have been performed in our and 
other institutions, within the period of up to three years 
prior to histology diagnosis. Mostly, the hrHPV detec-
tion method has not been recorded in the Hospital data-




The mean age for all 143 HSIL lesions has been 36,5 
(median 34; range 18–85). For the 13 cases of CIN2, the 
mean age has been 29.5 (median 28; range 20–47); for 
the 113 cases of CIN3, the mean age has been 36,0 (me-
dian 34; range 18–65); and for the 17 descriptive CIN 
cases, the mean age has been 43.2 (median 37; range 
27–85).
Cytologic-histologic correlation
The last cytology predicted CIN2 has been confi rmed 
histologically as CIN2 in 69% (9/13) of cases, whereas 
in 31% (4/13) of cases the cytology predicted CIN1 in-
stead. Regarding histological confi rmed CIN3, the 
 cytology predicted CIN3 in 70% (79/113) of cases, 
whereas the other results were classifi ed as CIN2 in 
17% (20/113) of cases, CIN1 in 8% (9/113) of cases, 
ASC-US in 4% (4/143) of cases and one negative case 
Pap test (0.7%;1/143) (Table 1.).




No. % No. (%)
Negative 1 0.9*
ASC-US 4 3.5
CIN1 4 30.8 9 7.9
CIN2 9 69.2 20 17.8
CIN3/ASC-H 79 69.9
Total 13 100 113 100
CIN1 – cervical intraepithelial neoplasia gradus 1; CIN2 – cervical intra-
epithelial neoplasia gradus 2; CIN3 – cervical intraepithelial neoplasia 
gradus 3; ASC-US – atypical squamous cells of undetermined signifi can-
ce; ASC-H – Atypical squamous cells-cannot exclude high-grade squa-
mous intraepithelial lesion. * CIN3 on cervical polyp
Prior PAP test results according 
to the time prior the biopsy
The cytology, analyzed within one year prior to HSIL 
biopsy, has predicted ASC-H/HSIL in 87% (125/143) of 
cases, while 12% (17/143) and 0.7% (1/143) have been 
reported as ASC-US/LSIL and negative respectively.
In the period of one to three years prior to histological 
diagnosis of HSIL 39 Pap results have been accessible 
and reported as: ASC-H/HSIL 67% (26/39), ASC-US/
LSIL 18% (7/39) and negative15% (6/39). For the 
 period of three to fi ve years of 29 available Pap test 
the reports have been: ASC-H/HSIL 34% (10/29), 
ASC-US/LSIL 24% (7/29) and negative 42% (12/29).
Prior hrHPV test results
The hrHPV test result have been negative for 20% 
(28/143) of HSIL biopsies. According to CIN2, CIN3 
and descriptive CIN hrHPV test was negative in 15% 
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(2/13), 19% (22/113) and 24% (4/17) respectively 
(Table 3.).
Prior hrHPV test results according to the age
The hrHPV test has been analyzed according to the 
age of patient as well. The hrHPV negative test has been 
found in 13% (5/39) of the age group 20–29, 21% (7/33) 
of the age group 30–34, and 22% (15/68) of the age 
group 35–65. Both women older than 65 were hrHPV 
positive, and one 18 years old was hrHPV negative 
(Table 4.).
Discussion
Cervical cytology has reduced morbidity and mortal-
ity in the last 70 years signifi cantly worldwide, but its 
limitations are well known.5,36,38 Due to direct relation-
ship between hrHPV infection and cervical carcinogen-
esis, it has been demonstrated that hrHPV infection is a 
necessary condition for the development of pre/invasive 
and invasive cervical cancer.4 As hrHPV types are de-
tected in more than 99% of invasive cancer cases and in 
the vast majority of high grade preinvasive cases, HPV 
detection may be a reasonable alternative as a screening 
test for the detection of precursor lesion that would 
progress to cancer if not treated.5,16,26 The superior sen-
sitivity of hrHPV testing is established in the literature, 
but there are variations in performance depending on 
the hrHPV method used and the study population.39,40
Cytologic-histologic correlation
Among the 143 patients with HSIL histological diag-
nosis the latest conventional Pap smear has been abnor-
mal in all but one case, 99.3% (142/143). Abnormal 
cytology reports have been CIN3 or ASC-H (87%;
125/143), CIN2 (23%;33/143), CIN1 (9%;13/143), and 
ASC-US (4%;4/143) cases.
Regarding the cytologic-histologic correlation, the 
69% (9/13) CIN2 has been correctly predicted by cytol-
ogy, while 31% (4/9) were underdiagnosed as CIN1. 
There have been no negative Pap smears, nor overdiag-
nosed cases in this group. Pajtler et al.,38 correctly pre-
dicted only 30% (8/27) of CIN2, while 22% (6/27) were 
underdiagnosed as CIN1, and 48% (13/27) were overdi-
agnosed as CIN3. Al-Nafussi et al.41 similar to Pajtler et 
al.38 correctly predicted CIN2 in 35% (103/292), and 
CIN1 in 22% (63/292), but 15% (45/292) were negative 
Pap reports, 9% (25/292) borderline and 19% (56/292) 
CIN3.41
According to our results, the histologic CIN3 has 
been correctly predicted in 70% (79/113) by cytology, 
whereas 17% (29/113) were underdiagnosed as CIN2, 
8% (9/113) as CIN1, 4% (4/113) as ASC-US and 0.7% 
(1/143) as negative report. The single negative case in-
volves a woman with cervical polyp, with the Pap smear 
that has been concomitantly collected with a polyp bi-
opsy. The histopathology report was CIN3 on the part of 
the endocervical polyp, while further cone biopsy has 
been negative for epithelial abnormalities. The Pap 
slide has been reviewed and no abnormalities have been 
Table 2. Prior Pap smear results according to time
Time preceding 
biopsy, years
Negative ASC-US/LSIL ASC-H / HSIL Total
No. % No. % No. % No. %
< 1 1 0.7 17 11.9 125 87.4 143 100
1–3 6 15.4 7 17.9 26 66.7 39 100
3–5 12 41.4 7 24.1 10 34.5 29 100
HSIL – high grade intraepithelial lesion; ASC-US – atypical squamous cells of undetermined signifi cance; LSIL – 
low grade intraepithelial lesion; ASC-H – atypical squamous cells-cannot exclude high-grade squamous intraepithe-
lial lesion.
Table 3. Prior hrHPV test according to histopathologic diagnosis
Descriptive CIN CIN2 CIN3 Total
No. % No. % No. % No. %
HPV+ 13 76 11 85 91 81 115 80
HPV– 4 24 2 15 22 19 28 20
Total 17 100 13 100 113 100 143 100
Descriptive CIN – descriptive histopathologic diagnosis due to damaged tissue, but suggesting HSIL;CIN2 – cervi-
cal intraepithelial neoplasia gradus 2; CIN3 – cervical intraepithelial neoplasia gradus 3; HPV+ – hrHPV (high risk 
human papillomavirus) test positive; HPV– – hrHPV test negative
Table 4. hrHPV test according to the age
Age HPV+ HPV– Total NNo. % No. % No.
< 20 1 100 1
20–29 34 87 5 13 39
30–34 26 79 7 21 33
35–65 53 78 15 22 68
>65 2 100 2
Total 115 80 28 20 143
HPV+ – hrHPV (high risk human papillomavirus) test positive; HPV– – 
hrHPV test negative
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found. However, this negative slide should be excluded 
according to recommendations, but this one was the 
only Pap smear available for analysis.35 Pajtler et al. re-
ported 90% (233/258) cytologic accuracy for CIN 3, 
while underdiagnoses were made as CIN2 and CIN1 in 
6% (16/258) and 3% (7/258) of cases respectively, and 
1% (2/258) were overdiagnosed as carcinoma.38 Al-Na-
fussi et al. confi rmed CIN3 correctly in 46% (178/383), 
whereas the negative Pap reports were in 2% (9/383), 
underdiagnosed as borderline, CIN1 and CIN2 in 7% 
(25/383), 14% (52/383), and 31% (119/383) respecti-
vely.41
The World Health Organization (WHO) introduced 
the two-tiered system for lower anogenital tract termi-
nology (LAST).4,42 Nevertheless, new studies confi rm 
the well known fact that CIN2 can regress spontane-
ously, especially in young women.4,43,44 Our results pres-
ent a rather minor proportion of underdiagnosed CIN2 
and CIN3 cases as well as Pajtler at al.38 Therefore, re-
taining subclassifi cation within three tiered system 
seems fully justifi ed, allowing individual approach that 
is of particular importance for young women planning 
pregnancy due to possible opstetric complications.45–47
Prior PAP test results according 
to the time prior the biopsy
Reports of our last cytology within one year prior to 
HSIL biopsy have predicted ASC-H/HSIL in 87% cas-
es, ASC-US/LSIL in 12% cases, with one additional 
negative case. Comparing to our results, four months 
prior to diagnostic biopsy, Zhao et al., among 2074 pa-
tients with LBC Pap test found 55% (1150/2074) ASC-
H/HSIL, 44% (909/2074) ASC-US/LSIL cases, and a 
few cases (1%;15/2074) of atypical glandular cells/ad-
enocarcinoma in situ (AGC/AIS).24
For more than a year prior to biopsy, data of Pap 
smears are limited in our Hospital database. Namely, 
most of the women have been previously followed at 
their primary care gynecologists, and their Pap smears 
have been analyzed in different laboratories. There were 
only 39 available Pap smears one to three years prior to 
biopsy reporting 67% (26/39) ASC-H/HSIL, 18% 
(7/39) ASC-US/LSIL whereas 15% (6/39) were nega-
tive. In similar period Zhao et al.24 found among 1488 
patients, 11% (166/1488) HSIL, 45% (673/1488) ASC-
US/LSIL, few AGC whereas 34% (510/1488) were 
negative. In the ARTISTIC trial19 during three year fol-
low up, for histology proven HSIL lesions the baseline 
Pap has been 55% (250/454) HSIL, 38% (171/454) 
ASC-US/LSIL and 7% (33/454) negative. In the PO-
BASCAM trial18 during the same follow up, for histol-
ogy proven HSIL the baseline cytology has been 47% 
HSIL (120/255), 25% (64/255) ASC-US/LSIL and 21% 
(70/255) negative.
In the period three to fi ve years prior to biopsy, 29 
Pap results were available in our Hospital database re-
porting 34% (10/29) ASC-H/HSIL, 24% (7/29) ASC-
US/LSIL with 42% (12/29) negative reports. The larg-
est comparable study is provided by Kaiser Permanente5 
on more than 330.000 women aged 30 and above, 
screened using conventional Pap smears. For 2223 pa-
tients with histology confi rmed HSIL, baseline cytolo-
gy (up to 5 year prior diagnosis) involved 18% 
(409/2223) ASC-H/HSIL, 33% (720/2223) ASC-US/
LSIL and 74% (1041/2223) negative.5 Almost 200.000 
women have been double negative Pap and hrHPV at 
enrollment, so that the second cotesting was performed 
up to three years after the enrolment. The HSIL have 
been detected in 333 cases: the second Pap smear has 
been 15% (49/333) ASC-H/HSIL, 54% (179/333) ASC-
US/LSIL and 28% (94/333) negative reported.5 Our 
study, as well as the others, strongly confi rm that more 
negative Pap smears are detected as the period prior to 
biopsy is increased.
Prior hrHPV test results
In our study the hrHPV testing prior to histologically 
proven HSIL was negative in 20% (28/143) cases. Zhao 
et al.24 in the period of 4 months to three years before 
HSIL biopsy identifi ed 24% (110/454) hrHPV negative 
test, similar to the Kaiser Permanente study5 with 20% 
(455/2223) baseline hrHPV negative tests, as well as 
19% (65/333) in the second hrHPV testing (in baseline 
double negative women). In the last published Kaiser 
Permanente results 16.1% (1602/9975) negative hrHPV 
tests were preceding biopsy proven CIN3.21 In contrast, 
the POBASCAM18 trial as well as ARTISTIC trial19 pre-
sented lower hrHPV negative rates preceding HSIL bi-
opsy, with 9% (23/255) and 7% (31/454) respectively.
Prior hrHPV test results according to age
Following European recommendations for cervical 
cancer screening6 the newest proposal of the Croatian 
working screening group suggest that primary hrHPV 
screening should be for the age group 35–65 years. 
However, the highest rate of negative hrHPV tests 
(22%;15/68) were found in this group. Similarly, in the 
age group of 30–35 and proposed screening by Pap and 
hrHPV cotesting, high number of hrHPV negative cases 
has also been found (21%;7/33). In the age group 20–29 
the lowest rate of negative hrHPV tests (13%; 5/39) 
confi rm the recommended proposal. Similar results for 
the younger age are presented in in histologically con-
fi rmed HSIL in the multicentric study of Castellsauge 
et al.48
Conclusion
Cytology in Croatia is well recognized as a method of 
cervical cancer screening30 and the results presented 
herein confi rm its reliability. Indeed, this research is 
suggestive that the possibility of the widespread re-
placement of cytology by hrHPV testing, should be sub-
ject to further investigation (such as a pilot study) and 
given careful consideration. Furthermore, in the context 
of potentially implementing hrHPV testing as the pri-
mary tool in the national organized cervical cancer 
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screening program in Croatia, the reliability of the dif-
ferent methods used for the detection of hrHPV should 
be established, since performance may vary between 
tests and countries. The reasons for hrHPV negative 
HSIL cases are often unclear and have been attributed 
to low viral load, inadequate sampling of infected cervi-
cal lesions, interfering substances, rare HPV genotypes, 
as well to a subset of the true non-HPV driven HSIL 
cases.23 Further investigation and larger sample size is 
necessary to distinguish between these possibilities.
Overall, the primary task for cervical cancer preven-
tion is to integrate as many women as possible into the 
nationally organized screening program. In this respect, 
the establishment of a national computerized database 
of clinic (colposcopic fi ndings) and laboratory (cytolo-
gy, histology and hrHPV) records would prove espe-
cially useful.
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CITOLOGIJA I HPV TESTIRANJE 
U OTKRIVANJU INTRAEPITELNIH PROMJENA 
VRATA MATERNIC E VISOKOG STUPNJA
Ana Barišić, Danijela Jurić, Sanda Rajhvajn, Lada Škopljanac Mačina, 
Ivana Šamija Projić, Iris Fabijanić, Marija Macan, Damir Babić, Vesna Mahovlić
Izvorni znanstveni rad
Ključne riječi:  Papanicolaou test; humani papilomavirus; cervikalna intraepitelna neoplazija; 
probir na karcinom cerviksa
SAŽETAK. Citološki probir ranog otkrivanja raka vrata maternice značajno je smanjio morbiditet i mortalitet od ove 
bolesti zadnjih pedesetak godina širom svijeta, a naročito u razvijenim zemljama koje već desetljećima provode sustavni 
nacionalni probir i imaju dostupne nacionalne baze podataka prethodnih citoloških, kolposkopskih, mikrobioloških i 
patohistoloških nalaza. Najvažniji cilj probira je otkrivanje rizične populacije prije nastanka invazivne bolesti kako bi 
liječenje bilo što manje invazivno. To je posebno važno zbog činjenice da često obolijevaju žene reproduktivne dobi koje 
još planiraju trudnoću. Boljim razumijevanjem karcinogeneze i uloge infekcije humanim papilomavirusom visokog 
 rizika (hrHPV) razvijeni su komercijalni testovi za otkrivanje ove infekcije i prije razvoja epitelnih promjena. Time je 
dodatno omogućeno produljenje vremenskog intervala probira. Hrvatski nacionalni program ranog citološkog otkrivanja 
raka vrata maternice pokrenut je nakon višedesetljetnih priprema krajem 2012., ali se zbog određenih nedostataka tre-
nutno revidira. Trenutni prijedlog pilot programa predviđa citološki probir žena dobne skupine 20 do 29 godina, kotesti-
ranje citologijom i hrHPV testa žena od 30 do 34 godine te primarno hrHPV testiranje žena od 35 do 65 godina.
Cilj ovog rada je doprinijeti izboru najbolje opcije za rani probir raka vrata maternice u Hrvatskoj.
Materijali i metode. U ovom retrospektivnom istraživanju analizirali smo dostupne podatke iz bolničkog informatičkog 
sustava (BIS) za žene kojima je tijekom 2016. godine u našem patohistološkom laboratoriju rađena analiza promjena 
vrata maternice. Izdvojene su 143 žene s patohistološkom dijagnozom intraepitelne promjene vrata maternice visokog 
stupnja (eng. HSIL) i dostupnim prethodnim nalazima citologije i hrHPV testiranja.
Rezultati. Prosječna dob žena bila je 36,5 godina s rasponom od 18 do 85 godina. Citološki nalaz predvidio je cervikalnu 
intraepitelnu neoplaziju CIN2 kod 69% (9/13) te CIN3 kod 70% (79/113) histoloških dijagnoza CIN2 i CIN3. U vre-
menskom razdoblju do godinu dana prije biopsije, citološki nalaz je bio abnormalan kod 99,3% (142/143) žena, u 12% 
(17/143) slučajeva atipične stanice skvamoznog epitela neodređenog značenja (eng. ASC-US) ili skvamozna intraepitel-
na neoplazija niskog stupnja (eng, LSIL) te u 87% (125/143) slučajeva skvamozna intraepitelna neoplazija visokog 
stupnja (eng. HSIL) ili atipične stanice skvamoznog epitela – ne može se iskljičiti HSIL (ASC-H). U vremenskom 
razdoblju od jedne do tri godine prije biopsije citološki nalaz je bio abnormalan kod 85% (33/39) žena, u 18% (7/39) 
slučajeva atipične stanice skvamoznog epitela neodređenog značenja (eng. ASC-US) ili skvamozna intraepitelna neopla-
zija niskog stupnja (eng, LSIL) te u 67% (26/39) slučajeva skvamozna intraepitelna neoplazija visokog stupnja (eng. 
HSIL) ili atipične stanice skvamoznog epitela – ne može se isključiti HSIL (ASC-H). U vremenskom razdoblju od tri do 
pet godina prije biopsije citološki nalaz je bio abnormalan kod 59% (17/29) žena, u 24% (7/29) slučajeva atipične stani-
ce skvamoznog epitela neodređenog značenja (eng. ASC-US) ili skvamozna intraepitelna neoplazija niskog stupnja 
(eng, LSIL) te u 35% (10/29) slučajeva skvamozna intraepitelna neoplazija visokog stupnja (eng. HSIL) ili atipične 
stanice skvamoznog epitela – ne može se isključiti HSIL (ASC-H). hrHPV test rađen unutar tri godine od biopsije bio je 
abnormalan u 80% (115/143) slučajeva. Prema dobnim skupinama hrHPV test je bio negativan u grupi 20 do 29 godina 
u 13% (5/39) slučajeva, u grupi 30 do 34 godina u 21% (7/33) te u grupi 35 do 65 godina u 22% (15/68).
Zaključak. Citologija je prepoznata kao dobra metoda probira raka vrata maternice posebno u Hrvatskoj gdje je ta grana 
medicine vrlo razvijena. Prikazani rezultati potvrđuju pouzdanost i dijagnostičku točnost ove metode. Prije prijelaza na 
primarni hrHPV probir trebalo bi napraviti dobro defi niranu pilot studiju koja uključuje kotestiranje. Pažljivo treba 
razmotriti koja metoda hrHPV tipizacije bi se uključila u primarni probir, jer različite metode u različitim sredinama 
nemaju iste rezultate. hrHPV negativni slučajevi HSIL-a kao i invazivnog karcinoma vrata maternice opisani su u 
brojnim radovima u literaturi, a najčešće se objašnjavaju kao: neadekvatno uzet uzorak za tipizaciju, malen broj čestica 
virusa u uzorku, onečišćenje uzorka tvarima koje ometaju analizu kao i malom broju zaista hrHPV negativnih slučajeva. 
Najvažniji cilj organiziranog nacionalnog probira je uključivanje što više žena u takav program. Da bi se to postiglo 
važno je uspostaviti nacionalnu bazu podataka koja uključuje citološke nalaze, rezultate hrHPV tipizacije uključujući 
točno korištenu metodu, kolposkopske te patohistološke nalaze.
